← Back to Clinical Trials
Recruiting NCT06614309

NCT06614309 Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06614309
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Long COVID
Study Type INTERVENTIONAL
Enrollment 45 participants
Start Date 2024-09-24
Primary Completion 2026-04

Trial Parameters

Condition Long COVID
Sponsor Mayo Clinic
Study Type INTERVENTIONAL
Phase N/A
Enrollment 45
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-09-24
Completion 2026-04
Interventions
Acute Placebo VisitAcute Progressive Carbon DioxideAcute Intermittent Hypoxia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome.

Eligibility Criteria

Inclusion criteria: * English speaking * Diagnosis of Long COVID Exclusion criteria: * Any history of: * Coronary artery dissection or aortic dissection * Neurological disease (e.g. dementia, Alzheimer's disease, or other brain-related disease) * Cerebrovascular disease or stroke * Aneurysm * If currently has: * Moderate-severe chronic obstructive pulmonary disease * Uncontrolled moderate-severe asthma * Moderate-severe bronchiectasis * Moderate-severe interstitial lung disease, requiring the use of supplemental oxygen * A necessity to use supplemental oxygen, for any reason * New or worsening symptoms (decompensation) of heart failure * Right heart disease due to chronic pulmonary disease/sleep apnea * Uncontrolled myocardial ischemia or angina * Uncontrolled heart arrhythmias * Heart or lung infection (e.g. myocarditis or pericarditis) * Left main coronary artery stenosis * Moderate-severe aortic stenosis * Pulmonary embolism, pulmonary infarction, or other blood clots * Severe respi

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology